Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

#4448

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Aim(s): To compare overall survival (OS) of sporadic GEP-NET that started simultaneously SSA and statin (S-group) towards patients who received only SSA (NS-group).

Materials and methods: Retrospective analysis was conducted on patients with sporadic GEP-NET referred to ENETS CoE of the University Federico II of Naples between 2016 and 2024.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,